Posted by Michael Wonder on 08 Dec 2023
FDA approves first gene therapies to treat patients with sickle cell disease
8 December 2023 - Today, the US FDA approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years and older.
Additionally, one of these therapies, Casgevy, is the first FDA approved treatment to utilise a type of novel genome editing technology, signalling an innovative advancement in the field of gene therapy.
